{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:30:15Z","timestamp":1763706615838,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cld.2023.06.001","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T16:19:04Z","timestamp":1690474744000},"page":"791-808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chronic Hepatitis B"],"prefix":"10.1016","volume":"27","author":[{"given":"Feng","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2023.06.001_bib1","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.06.001_bib2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address eee, European association for the study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2023.06.001_bib4","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.06.001_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B","volume":"143","author":"Kennedy","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.06.001_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2023.06.001_bib7","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1093\/cid\/ciac383","article-title":"Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion","volume":"76","author":"Chow","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2023.06.001_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jvh.12370","article-title":"Treating immune-tolerant hepatitis B","volume":"22","author":"Tseng","year":"2015","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2023.06.001_bib9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/17474124.2017.1361822","article-title":"Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis","volume":"11","author":"Okada","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.06.001_bib12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2023.06.001_bib13","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/gutjnl-2012-302024","article-title":"Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis","volume":"62","author":"Zoutendijk","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.06.001_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.06.001_bib15","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ajg.2014.145","article-title":"Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis","volume":"109","author":"Kim","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2023.06.001_bib16","unstructured":"(WHO) WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection."},{"key":"10.1016\/j.cld.2023.06.001_bib17","first-page":"769","article-title":"Guidelines for prevention and treatment of chronic hepatitis B","volume":"9","author":"Wang","year":"2021","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib18","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.cgh.2021.07.036","article-title":"Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update","volume":"20","author":"Martin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.gastha.2022.10.004","article-title":"It is time for a simplified approach to hepatitis B elimination","volume":"2","author":"Dieterich","year":"2023","journal-title":"Gastro Hep Advances"},{"key":"10.1016\/j.cld.2023.06.001_bib20","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.cgh.2021.01.019","article-title":"Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase","volume":"20","author":"Huang","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cgh.2019.05.024","article-title":"The HBeAg-negative \"gray zone\" phase: a frequent condition with different outcomes in western and asian patients?","volume":"18","author":"Bonacci","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib22","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/apt.14613","article-title":"Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone","volume":"47","author":"Bonacci","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2023.06.001_bib23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3350\/cmh.2017.0068","article-title":"Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend","volume":"24","author":"Wong","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coviro.2018.03.006","article-title":"Why, who and when to start treatment for chronic hepatitis B infection","volume":"30","author":"Dolman","year":"2018","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.cld.2023.06.001_bib25","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1053\/j.gastro.2020.02.027","article-title":"Closing the stable door after the horse has bolted: should we Be treating people with immune-tolerant chronic hepatitis B to prevent hepatocellular carcinoma?","volume":"158","author":"Howell","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.06.001_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/v14050900","article-title":"Early Treatment Consideration in Patients with Hepatitis B 'e' Antigen-Positive Chronic Infection: is It Time for a Paradigm Shift?","volume":"14","author":"Koffas","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.cld.2023.06.001_bib27","doi-asserted-by":"crossref","first-page":"104783","DOI":"10.1016\/j.antiviral.2020.104783","article-title":"Reasons to consider early treatment in chronic hepatitis B patients","volume":"177","author":"Koffas","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cld.2023.06.001_bib28","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/gutjnl-2020-323153","article-title":"Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma","volume":"71","author":"Peneau","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.06.001_bib29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","article-title":"Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.06.001_bib30","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2021.12.286","article-title":"Inhibition of viral replication reduces transcriptionally active distinct hepatitis B virus integrations with implications on host gene dysregulation","volume":"162","author":"Hsu","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.06.001_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02007-17","article-title":"Hepatitis B virus DNA integration occurs early in the viral life cycle in an in\u00a0vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles","volume":"92","author":"Tu","year":"2018","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cld.2023.06.001_bib32","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.06.001_bib33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MCG.0000000000000852","article-title":"Four-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patients","volume":"52","author":"Wong","year":"2018","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cld.2023.06.001_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpeds.2005.09.020","article-title":"Combined lamivudine\/interferon-alpha treatment in \"immunotolerant\" children perinatally infected with hepatitis B: a pilot study","volume":"148","author":"D'Antiga","year":"2006","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.cld.2023.06.001_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/jvh.12007","article-title":"Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon?","volume":"20","author":"Poddar","year":"2013","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2023.06.001_bib36","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.30417","article-title":"Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection","volume":"69","author":"Feld","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.06.001_bib37","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1002\/hep.30654","article-title":"Immune-tolerant hepatitis B: maybe a misnomer but still hard to treat","volume":"69","author":"Martin","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.06.001_bib38","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.06.001_bib39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3350\/cmh.2020.0216","article-title":"Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B","volume":"27","author":"Jeon","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/apt.15741","article-title":"Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase","volume":"52","author":"Lee","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2023.06.001_bib41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2020.10.022","article-title":"Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B","volume":"84","author":"Lee","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cld.2023.06.001_bib42","doi-asserted-by":"crossref","DOI":"10.21037\/amj.2018.02.01","article-title":"Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy?","volume":"3","author":"Zhou","year":"2018","journal-title":"AME Med J"},{"key":"10.1016\/j.cld.2023.06.001_bib43","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/cid\/ciw516","article-title":"Infrequent clinical assessment of chronic hepatitis B patients in United States general healthcare settings","volume":"63","author":"Spradling","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cld.2023.06.001_bib44","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12072-021-10137-2","article-title":"Chronic hepatitis B: the demise of the 'inactive carrier' phase","volume":"15","author":"Koffas","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2023.06.001_bib45","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jvh.12643","article-title":"Determination of hepatitis B phenotype using biochemical and serological markers","volume":"24","author":"Di Bisceglie","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2023.06.001_bib46","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/ajg.2009.248","article-title":"Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels","volume":"104","author":"Nguyen","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2023.06.001_bib47","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","article-title":"The clinical significance of persistently normal ALT in chronic hepatitis B infection","volume":"47","author":"Lai","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib48","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.06.001_bib49","doi-asserted-by":"crossref","first-page":"1035923","DOI":"10.3389\/fimmu.2022.1035923","article-title":"Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone","volume":"13","author":"Ren","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cld.2023.06.001_bib50","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/apt.17272","article-title":"Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone","volume":"57","author":"Wang","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2023.06.001_bib51","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/jvh.13511","article-title":"Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone","volume":"28","author":"Yao","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2023.06.001_bib52","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/jvh.13185","article-title":"The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria","volume":"26","author":"Sinn","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2023.06.001_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/apt.15311","article-title":"High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation","volume":"50","author":"Choi","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2023.06.001_bib54","doi-asserted-by":"crossref","first-page":"e00036","DOI":"10.14309\/ctg.0000000000000036","article-title":"Prognosis of untreated minimally active chronic hepatitis B patients in comparison with virological responders by antivirals","volume":"10","author":"Lee","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cld.2023.06.001_bib55","first-page":"S1","article-title":"Updated evaluation of global progress towards HBV and HCV elimination, preliminary data through 2021","volume":"76","author":"Blach","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.06.001_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","author":"Hsu","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jhep.2021.08.019","article-title":"Substantial gaps in evaluation and treatment of patients with hepatitis B in the US","volume":"76","author":"Ye","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib58","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Polaris Observatory","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib59","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jhep.2016.10.013","article-title":"Battlefield against hepatitis B infection and HCC in africa","volume":"66","author":"Lemoine","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.06.001_bib60","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1136\/gutjnl-2020-321309","article-title":"Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B","volume":"70","author":"Kim","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cld.2023.06.001_bib61","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/apt.17052","article-title":"Impact of expanding hepatitis B treatment guidelines: a modelling and economic impact analysis","volume":"56","author":"Lim","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2023.06.001_bib62","doi-asserted-by":"crossref","first-page":"253","DOI":"10.14309\/ajg.0000000000001575","article-title":"Hepatitis B virus infection and extra-hepatic manifestations: a systemic disease","volume":"117","author":"Cacoub","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2023.06.001_bib63","article-title":"Extrahepatic manifestations of chronic HBV infection and the role of antiviral therapy","volume":"11","author":"Mazzaro","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cld.2023.06.001_bib64","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.md.0000180792.80212.5e","article-title":"Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients","volume":"84","author":"Guillevin","year":"2005","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.cld.2023.06.001_bib65","doi-asserted-by":"crossref","first-page":"1095780","DOI":"10.3389\/fonc.2023.1095780","article-title":"Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: a review of the literature","volume":"13","author":"Mazzaro","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.cld.2023.06.001_bib66","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/jvh.13451","article-title":"Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV","volume":"28","author":"Younossi","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cld.2023.06.001_bib67","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/jvh.13838","article-title":"Measuring stigma associated with hepatitis B virus infection in Sierra Leone: validation of an abridged Berger HIV stigma scale","volume":"30","author":"Yendewa","year":"2023","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cld.2023.06.001_bib68","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s41687-021-00398-8","article-title":"Health-related quality of life for adults living with hepatitis B in the United States: a qualitative assessment","volume":"5","author":"Freeland","year":"2021","journal-title":"J\u00a0Patient Rep Outcomes"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:59:27Z","timestamp":1761069567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326123000739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1089326123000739"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.06.001","relation":{},"ISSN":["1089-3261"],"issn-type":[{"type":"print","value":"1089-3261"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}